Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk

Campbell D Joyner, Ron J G Peters, Rizwan Afzal, Susan Chrolavicius, Shamir R Mehta, Keith A A Fox, Christopher B Granger, Maria Grazia Franzosi, Marcus Flather, Andrzej Budaj, Jean-Pierre Bassand, Salim Yusuf

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)


The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%. The objectives of our study were to assess the effects of fondaparinux compared to enoxaparin in patients stratified by their Global Registry of Acute Coronary Events (GRACE) score and to examine the ability of the GRACE score to predict bleeding in patients with acute coronary syndromes (ACS).
Original languageEnglish
Pages (from-to)502-8
Number of pages7
JournalAmerican Heart Journal
Issue number3
Publication statusPublished - Mar 2009


  • Acute Coronary Syndrome
  • Anticoagulants
  • Enoxaparin
  • Hemorrhage
  • Humans
  • Polysaccharides
  • Prognosis
  • Risk Assessment
  • Treatment Outcome

Cite this